Transcript
Page 1: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

BLOOD FORMING AGENTSBLOOD FORMING AGENTS

Page 2: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Clinical ThrombosisClinical Thrombosis

• > 2.5 million cases of deep venous 2.5 million cases of deep venous thrombosis (DVT) annually thrombosis (DVT) annually

• > 600.000 cases of pulmonary > 600.000 cases of pulmonary embolism (PE) per yearembolism (PE) per year

• > 50.000 deaths per year from PE> 50.000 deaths per year from PE

• > 11.000 post surgical PE deaths per > 11.000 post surgical PE deaths per yearyear

Page 3: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 4: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 5: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 6: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 7: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 8: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Anti Platelet DrugsAnti Platelet DrugsDrugDrug MechanismMechanism UsesUses

AspirinAspirin Permanently inhibits Permanently inhibits

COX-1COX-1 and COX-2 and COX-2

CAD (CAD (coronary artery coronary artery disease)disease)

Stroke-TIAs (Stroke-TIAs (transient transient ischemic attack)ischemic attack)

NSAIDsNSAIDs Reversibly inhibits Reversibly inhibits

COX-1COX-1

LimitedLimited

DipyridamoleDipyridamole Inhibits PDE; increases cAMPInhibits PDE; increases cAMP TIAsTIAs

TiclopidineTiclopidine

ClopidogrelClopidogrel

Inhibits ADP; Inhibits ADP;

active metaboliteactive metabolite

TIAs; StrokeTIAs; Stroke

CAD; PVD (CAD; PVD (peripheral peripheral vascular disease)vascular disease)

Page 9: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

INHIBITORS OF PLATELET AGGREGATIONINHIBITORS OF PLATELET AGGREGATION

Page 10: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Platelets inhibitors - ASAPlatelets inhibitors - ASA

Daily dose -Daily dose - 80- 80-1100 00 mgmg

KardiomagnilKardiomagnil

Page 11: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

ANTIPLATELET THERAPYANTIPLATELET THERAPY

Aspirin IndicationsAspirin Indications

1)1) Stroke, TIA (transient ischemic Stroke, TIA (transient ischemic attacks)attacks)

2)2) MI, recurrent MIMI, recurrent MI3)3) Unstable anginaUnstable angina

4)4) CABG potency (CABG potency (coronary coronary artery bypass graftartery bypass graft ))

Page 12: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

TICLOPIDINETICLOPIDINE

1)1) Interferes with platelet-fibrinogen binding Interferes with platelet-fibrinogen binding 2)2) Exerts its action for the life of the plateletExerts its action for the life of the platelet3)3) May prolong bleeding timeMay prolong bleeding time4)4) Useful for coronary artery stents and CVA Useful for coronary artery stents and CVA

((cerebrovascular accidentcerebrovascular accident ))5)5) Methylprednisolone may reverse its effectMethylprednisolone may reverse its effect6)6) Associated with TTP (Associated with TTP (thrombocytopenic thrombocytopenic

purpurapurpura), neutropenia, and diarrhea ), neutropenia, and diarrhea

Page 13: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

CLOPIDOGRELCLOPIDOGREL

1)1) Interferes with GP IIb/IIIa Interferes with GP IIb/IIIa

((Glycoprotein IIbGlycoprotein IIb// IIIa IIIa ) binding site ) binding site

2)2) Exerts its action for the life of the plateletExerts its action for the life of the platelet

3)3) May prolong bleeding timeMay prolong bleeding time

4)4) Indicated for prevention of MI, CVA Indicated for prevention of MI, CVA ((cerebrovascular accidentcerebrovascular accident)), and vascular death, and vascular death

5)5) Fewer side effects than ticlopidineFewer side effects than ticlopidine

6)6) Dose: 75 mg daily Dose: 75 mg daily

Page 14: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Abciximab (ReoPro)Abciximab (ReoPro)

1)1) Human-mouse monoclonal Human-mouse monoclonal antibodiesantibodies

2)2) Binds to GP (glycoprotein) IIb/IIIa Binds to GP (glycoprotein) IIb/IIIa receptor on plateletsreceptor on platelets

3)3) Half-life 10 min.Half-life 10 min.

4)4) May block receptor for 10 daysMay block receptor for 10 days

5)5) Indicated for prevention of closure of Indicated for prevention of closure of coronary vessels after angioplastycoronary vessels after angioplasty

6)6) May cause thrombocytopeniaMay cause thrombocytopenia

7)7) Used with heparin and ASAUsed with heparin and ASA

Page 15: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Antiplatelet therapyAntiplatelet therapy

Page 16: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 17: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 18: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 19: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 20: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 21: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 22: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Mechanism of heparin actionMechanism of heparin action

АТ ІІІ ІІ а АТ ІІІ Х аХ а55

13

АТ ІІІ – ant thrombin ІІІІІ а – thrombin

Х а – prothrombinase (Stuart-Prover factor)

10

Page 23: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 24: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

IV or SC administration onlyIV or SC administration only

HEPARINHEPARIN

Page 25: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

HEPARIN (Indications)HEPARIN (Indications)

Full Dose:Full Dose: 5000 U or 80 U/kg 5000 U or 80 U/kg IVIV bolus, followed by 1200-1600 bolus, followed by 1200-1600 U/hr adjusted to therapeutic range U/hr adjusted to therapeutic range 1)1) Acute deep venous thrombosisAcute deep venous thrombosis 2)2) Pulmonary emboliPulmonary emboli 3)3) Unstable angina and myocardial infarctionUnstable angina and myocardial infarctionLow Dose:Low Dose: 5000 U 5000 U sqsq q12 h q12 h 1)1) Postoperative prophylaxis of any major abdominal, Postoperative prophylaxis of any major abdominal, thoracic, gynecologic, or orthopedic procedurethoracic, gynecologic, or orthopedic procedure 2)2) Immobilized medical patients >40 yrs. with CHF, CVA, Immobilized medical patients >40 yrs. with CHF, CVA,

malignant diseasemalignant disease 3)3) Prophylaxis for underlying hypercoagulable stateProphylaxis for underlying hypercoagulable stateOther Dose:Other Dose: 1)1) Extracorporeal bypassExtracorporeal bypass 2)2) HemodialysisHemodialysis 3)3) AfterAfter thrombolytic therapy thrombolytic therapy

Page 26: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

HEPARIN (Contraindications)HEPARIN (Contraindications)

11)) ThrombocytopeniaThrombocytopenia2)2) Aspirin or alcohol useAspirin or alcohol use3)3) Hepatic or renal diseaseHepatic or renal disease4)4) Other platelet dysfunctionOther platelet dysfunction5)5) GI bleedingGI bleeding6)6) TumorsTumors

Page 27: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

HEPARIN (Side Effects)HEPARIN (Side Effects)

1)1) Major side effect is bleedingMajor side effect is bleeding

2)2) Osteoporosis with prolonged Osteoporosis with prolonged useuse

3)3) ThrombocytopeniaThrombocytopenia

w

Page 28: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

HEPARIN-INDUCED THROMBOCYTOPENIAHEPARIN-INDUCED THROMBOCYTOPENIA 1)1) Occurs in 2-5% of patients receiving standard Occurs in 2-5% of patients receiving standard

heparin by heparin by immune mechanismimmune mechanism

2)2) May occur with minute doses, including heparin May occur with minute doses, including heparin flushesflushes

3)3) More common with bovine than porcine heparinMore common with bovine than porcine heparin

4)4) Asymptomatic thrombocytopenia can occur in 30-Asymptomatic thrombocytopenia can occur in 30-50% of pts who develop HIT antibodies 50% of pts who develop HIT antibodies

5)5) ~~20-50% of thrombocytopenic patients develop 20-50% of thrombocytopenic patients develop arterial or venous thrombosis that may be life arterial or venous thrombosis that may be life threatening threatening

Page 29: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

1)1) LepirudinLepirudin

2)2) Argatroban Argatroban

HEPARIN-INDUCED HEPARIN-INDUCED THROMBOCYTOPENIA THROMBOCYTOPENIA

Alternative Anticoagulants- Alternative Anticoagulants- direct direct thrombin inhibitorsthrombin inhibitors

Page 30: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

LOW MOLECULAR WEIGHT LOW MOLECULAR WEIGHT HEPARINHEPARIN

1) 1) Molecular weight 3,000- 7,000 DMolecular weight 3,000- 7,000 D

2)2) Inhibits factor Xa rather than thrombinInhibits factor Xa rather than thrombin

3)3) Factor Xa assay used for monitoringFactor Xa assay used for monitoring

4)4) Administered Administered subcutaneously 2 times/dsubcutaneously 2 times/d

5)5) Probably less antigenic than standard Probably less antigenic than standard heparinheparin

6)6) Recommended for prophylaxis and Recommended for prophylaxis and treatmenttreatment

Page 31: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 32: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

LOW MOLECULAR WEIGHT LOW MOLECULAR WEIGHT HEPARINHEPARIN

1) 1) PT, APTT not usually prolongedPT, APTT not usually prolonged

2) 2) May be May be monitored with anti-factor Xa monitored with anti-factor Xa assayassay

Page 33: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj

Page 34: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

LOW MOLECULAR WEIGHT HEPARINSLOW MOLECULAR WEIGHT HEPARINS

ggggggggggggggggggg

Page 35: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 36: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Indications for and Contraindications to Parenteral Anticoagulant Agents

Anticoagulant Agent Class Approved & Appropriate Indications

Contraindication

Unfractionated heparin

Enoxaparin(Lovenox)

Dalteparin(Fragmin)

Tinzaparin(Innohep)

Antithrombin III inhibitor

Low-molecular-weight heparin

Low-molecular-weight heparin

Low-molecular-weight heparin

Treatment of venous thromboembolism or unstable angina; used when rapid reversal is important

Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina

Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism or unstable angina

Prophylaxis in moderate-risk or high-risk patients, treatment of venous thromboembolism

?Prophylactic treatment

Regional anesthesia

Pregnancy

Prosthetic Heart Valves

Regional anesthesia

Regional anesthesia

Page 37: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Heparin-Antibiotic InteractionsHeparin-Antibiotic Interactions

• The cephalosporins- The cephalosporins- cefamandole, cefotetan, cefamandole, cefotetan, and cefoperazoneand cefoperazone, contain an N-, contain an N-methylthiotetrazole (NMTT) side chain. This methylthiotetrazole (NMTT) side chain. This NMTT group can:NMTT group can:

• - Dissociate from the parent antibiotic in solution - Dissociate from the parent antibiotic in solution or in vivo and or in vivo and competitively inhibit vitamin K competitively inhibit vitamin K action, leading to prolongation of the action, leading to prolongation of the prothrombin time and bleeding. prothrombin time and bleeding.

• - This side chain is also associated with a - This side chain is also associated with a disulfiram-like reaction to alcoholdisulfiram-like reaction to alcohol..

Page 38: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 39: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 40: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 41: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

ANTICOAGULANTS ANTICOAGULANTS OF INDIRECT ACTIONOF INDIRECT ACTION

COUMARIN (Description)COUMARIN (Description) 1)1) Isolated by Link in 1939 after previous Isolated by Link in 1939 after previous

observation that cattle developed observation that cattle developed bleeding bleeding disorder after ingestion of spoiled disorder after ingestion of spoiled cloverclover2)2) Is 4-hydroxycoumarin compound, similar Is 4-hydroxycoumarin compound, similar in structure to vitamin Kin structure to vitamin K3)3) Administered p.o., rapid GI absorptionAdministered p.o., rapid GI absorption4)4) Crosses placenta easily (complications!)Crosses placenta easily (complications!)5)5) Interacts with a variety of drugsInteracts with a variety of drugs

Page 42: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 43: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

LIVERLIVER

Page 44: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

COUMARINCOUMARIN (Actions) (Actions)

1)1) Blocks the carboxylation of the Blocks the carboxylation of the vitamin K dependent clotting vitamin K dependent clotting proteins, factors II, VII, IX, and X, proteins, factors II, VII, IX, and X, maintaining them in their maintaining them in their inactive formsinactive forms

2) Blocks the anticoagulant proteins 2) Blocks the anticoagulant proteins C and S C and S

3) 3) Onset – 18-48 hoursOnset – 18-48 hours

Page 45: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

COUMARIN COUMARIN LaboratoryLaboratory

1)1) Prolongs the PT and APTTProlongs the PT and APTT

2)2) PT and Prothrombin index -used PT and Prothrombin index -used for monitoring for monitoring

Page 46: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Prothrombin indexProthrombin index INTERNATIONAL NORMALIZED RATIO INTERNATIONAL NORMALIZED RATIO

(INR)(INR)

INR = INR = PATIENT PTPATIENT PT

CONTROL PTCONTROL PT

Decrease no less than 50 %Decrease no less than 50 %

Page 47: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

COUMARIN COUMARIN Side EffectsSide Effects

1)1) HemorrhageHemorrhage

2) Fetal abnormalities2) Fetal abnormalities

3)3) Skin necrosis with deficiencies of Skin necrosis with deficiencies of proteins proteins C or S usually on 3rd to 8th C or S usually on 3rd to 8th day of therapyday of therapy

Page 48: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

COUMARINCOUMARIN InteractionsInteractionsPOTENTIATORS :POTENTIATORS :

PhenylbutazonePhenylbutazoneCimetidineCimetidineOmeprazoleOmeprazoleAmiodaroneAmiodaroneAnabolic steroidsAnabolic steroids

ANTAGONISTS :ANTAGONISTS :BarbituratesBarbituratesRifampinRifampinPenicillinsPenicillinsAntacidsAntacids

Page 49: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 50: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 51: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 52: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)
Page 53: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Pharmacodynamics of fibrinolytic drugsPharmacodynamics of fibrinolytic drugs

• After introduction into organism they After introduction into organism they cause lyses of cause lyses of freshfresh (24-72 (24-72 hourshours) ) thrombi in arteries, veins, cavitiesthrombi in arteries, veins, cavities

• The most effective during the first 2-3 The most effective during the first 2-3 hours after initiation of thrombosishours after initiation of thrombosis

Page 55: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

HAEMOSTATICS HAEMOSTATICS with systemic actionwith systemic action

FibrinogenFibrinogen, , Calcium chlorideCalcium chloride, , vitamin vitamin К, К, VikasolumVikasolum

Page 56: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

INHIBITORS OF FIBRINOLYSISINHIBITORS OF FIBRINOLYSISof direct action (Contrikal, Trasilol, Gordox)of direct action (Contrikal, Trasilol, Gordox)

of indirect action of indirect action ((Ac aminocapronicum, Ac. tranexamicumAc aminocapronicum, Ac. tranexamicum, , AmbenAmben))

Page 63: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Ginkgo bilobaGinkgo biloba(Maidenhair-tree)(Maidenhair-tree)

TanakanTanakan

Page 64: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

DRUGS EFFECTING DRUGS EFFECTING HAEMOPOESISHAEMOPOESIS

Page 65: BLOOD FORMING AGENTS. Clinical Thrombosis 2.5 million cases of deep venous thrombosis (DVT) annually> 2.5 million cases of deep venous thrombosis (DVT)

Food products with ironFood products with iron

MeatMeatSoybeansSoybeans

Dry smoked plumsDry smoked plumsSpinachSpinach

Dry apricotsDry apricotsBuckwheatBuckwheat

RiceRiceBreadBread

Fruits of Fruits of pomegranate pomegranate

Iron from animal products absorbs much Iron from animal products absorbs much more better than from plants (more better than from plants (22 %22 % and 1 % and 1 %))


Recommended